Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Campylobacter pylori

Aliment Pharmacol Ther. 1990 Feb;4(1):49-54. doi: 10.1111/j.1365-2036.1990.tb00448.x.

Abstract

Sixty consecutive patients with endoscopically proven duodenal ulcers were given colloidal bismuth subcitrate tablets either as 120 mg q.d.s. or 240 mg b.d., in a randomized single-blind study. The efficacy of each regimen was determined by endoscopic examination and antral biopsy at 4 weeks; if the ulcer remained unhealed, treatment was continued and endoscopy repeated at 8 weeks. The ulcer-healing efficacy of the two regimens was identical; however, in the four times daily group only 27% remained Campylobacter pylori positive after 8 weeks of treatment compared with 58% of the twice-daily group. Similarly, only 21% of twice daily patients were free of histological gastritis compared with 42% of the four times daily patients.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Anti-Ulcer Agents / administration & dosage
  • Anti-Ulcer Agents / therapeutic use*
  • Colloids
  • Duodenal Ulcer / drug therapy*
  • Duodenal Ulcer / microbiology
  • Duodenal Ulcer / pathology
  • Endoscopy, Gastrointestinal
  • Gastritis / drug therapy
  • Gastritis / pathology
  • Helicobacter pylori / drug effects*
  • Humans
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / therapeutic use*
  • Single-Blind Method

Substances

  • Anti-Ulcer Agents
  • Colloids
  • Organometallic Compounds
  • bismuth tripotassium dicitrate